Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)

W. W. Tan, D. W. Hillman, M. Salim, D. W. Northfelt, D. M. Anderson, P. J. Stella, R. Niedringhaus, A. M. Bernath, S. S. Gamini, F. Palmieri, E. A. Perez

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)'. Together they form a unique fingerprint.

Medicine & Life Sciences